Single therapy offers improved survival in younger patients with limited brain metastases

Share this content:

the ONA take:

A study that analyzed patient data from the three largest randomized clinical trials of stereotactic radiosurgery (SRS) and whole brain radiation therapy (WBRT) found that in patients with cancer who are ages 50 years and younger should receive SRS without WBRT.

The meta-analysis examined data from a total of 364 patients from an Asian trial (JROSG99-1), published in 2006; a North American trial (MDACC NCT00548756), published in 2009; and a European trial (EORTC 22952-26001), published in 2011.

The data showed that SRS alone yielded improved overall survival (OS) in patients ages 50 years and younger. Median survival for these patients was 13.6 months after treatment with SRS alone, whereas patients in the same age group who received SRS plus WBRT had a median survival of 8.2 months.

Patients older than 50 years who underwent SRS along had a median survival of 10.1 months, and 8.6 months for those who received SRS plus WBRT.

The researchers reported expecting to see improved survival in patients who received therapy combining SRS and WBRT.

However, these data clearly demonstrated SRS alone offered benefits for younger patients with limited metastases.

Brain mets
Data clearly demonstrated stereotactic radiosurgery alone offered benefits for younger patients with limited metastases.
Cancer patients with limited brain metastases (one to four tumors) who are 50 years old and younger should receive stereotactic radiosurgery (SRS) without whole brain radiation therapy (WBRT), according to a study.
READ FULL ARTICLE From Medical Express
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs